Muscarinic Receptors: Their Roles in Disorders of the Central Nervous System and Potential as Therapeutic Targets

CNS Neuroscience and Therapeutics

Volumn 18, Issue 5, 2012, Pages 369-379

  Scarr, Elizabeth ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Acetylcholine; Alzheimer's disease; Bipolar disorder; Major depressive disorder; Parkinson's disease; Schizophrenia; Substance abuse

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; BUNGAROTOXIN RECEPTOR; DONEPEZIL; GAMMA SECRETASE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; LIGAND; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 5; MUSCARINIC RECEPTOR; NEUROTRANSMITTER; PHYSOSTIGMINE; RIVASTIGMINE; SCOPOLAMINE; XANOMELINE;

ALZHEIMER DISEASE; ANXIETY DISORDER; BINDING AFFINITY; BIPOLAR DISORDER; BRAIN STEM; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC SYSTEM; COCAINE DEPENDENCE; ENZYME ACTIVITY; FOREBRAIN; HIPPOCAMPUS; HOMEOSTASIS; HUMAN; INTERNEURON; MAJOR DEPRESSION; MOLECULARLY TARGETED THERAPY; NERVE PROJECTION; NEUROFIBRILLARY TANGLE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SCHIZOPHRENIA; SENILE PLAQUE; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; TARGET VARIABLE; TREATMENT DURATION;

ACETYLCHOLINE; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CHOLINERGIC AGENTS; HUMANS; RECEPTORS, MUSCARINIC;

EID: 84860315449     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00249.x     Document Type: Review

References (126)

1. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. Br J Pharmacol 2008;154:1558-1571.
2. Ismail N, Robinson GE, Fahrbach SE. Stimulation of muscarinic receptors mimics experience-dependent plasticity in the honey bee brain. Proc Natl Acad Scie USA 2006;103:207-211.
3. Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis. Brain Res Rev 1997;23:28-46.
4. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: A neurotransmitter correlate of consciousness Trends Neurosci 1999;22:273-280.
5. Dale HH. The action of certain esters and ethers of choline and their relation to muscarine. J Pharmacol Exp Ther 1914;6:147-190.
6. Lucas-Meunier E, Fossier P, Baux G, Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Archiv Eur J Physiol 2003;446:17-29.
7. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-290.
8. Felder CC. Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. FASEB J 1995;9:619-625.
9. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995;64:1888-1891.
10. Mrzljak L, Levey AI, Goldman-Rakic PS. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: Morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 1993;90:5194-5198.
11. Harrison PJ, Barton AJ, Najlerahim A, McDonald B, Pearson RC. Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry. Brain Res Mol Brain Res 1991;9:15-21.
12. Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 2002;22:1709-1717.
13. Mrzljak L, Levey AI, Belcher S, Goldman-Rakic PS. Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey. J Comp Neurol 1998;390:112-132.
14. Disney AA, Aoki C. Muscarinic acetylcholine receptors in macaque V1 are most frequently expressed by parvalbumin-immunoreactive neurons. J Comp Neurol 2008;507:1748-1762.
15. Levey AI, Edmunds SM, Heilman CJ, Desmond TJ, Frey KA. Localization of muscarinic M3 receptor protein and M3 receptor binding in rat brain. Neuroscience 1994;63:207-221.
16. Weiner DM, Levey AI, Brann MR. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 1990;87:7050-7054.
17. Vilaro MT, Palacios JM, Mengod G. Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett 1990;114:154-159.
18. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 2001;98:15312-15317.
19. Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 2001;21:5239-5250.
20. Shinoe T, Matsui M, Taketo MM, Manabe T. Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J Neurosci 2005;25:11194-11200.
21. Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51-58.
22. Tzavara ET, Bymaster FP, Felder CC, et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 2003;8:673-679.
23. Gomeza J, Shannon H, Kostenis E, et al. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999;96:1692-1697.
24. Yamada M, Miyakawa T, Duttaroy A, et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001;410:207-212.
25. Salamone JD, Correa M, Carlson BB, et al. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sci 2001;68:2579-2584.
26. Gomeza J, Zhang L, Kostenis E, et al. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999;96:10483-10488.
27. Tzavara ET, Bymaster FP, Davis RJ, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: Relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004;18:1410-1412.
28. Yamada M, Basile AS, Fedorova I, et al. Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci 2003;74:345-353.
29. Basile AS, Fedorova I, Zapata A, et al. Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci USA 2002;99:11452-11457.
30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th - text revision ed. Washington, DC : American Psychiatric Association, 2000.
31. Jablensky A. Subtyping schizophrenia: Implications for genetic research. Mol Psychiatry 2006;11:815-836.
32. Cohen LH, Thale T, Tissenbaum MJ. Acetylcholine treatment of schizophrenia. Arch Neurol Psychiatry 1944;51:171-175.
33. Forrer GR, Miller JJ. Atropine Coma: A somatic therapy in psychiatry. Am J Psychiatry 1958;115:455-458.
34. Scarr E, Dean B. Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Rev Neurother 2009;9:73-86.
35. Liao DL, Hong CJ, Chen HM, et al. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003;48:72-76.
36. Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003;119:2-6.
37. Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 2009;14:1017-1023.
38. De Luca V, Wang H, Squassina A, Wong GW, Yeomans J, Kennedy JL. Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 2004;50:124-127.
39. Bennett JP Jr., Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979;36:927-934.
40. Watanabe S, Nishikawa T, Takashima M, Toru M. Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 1983;33:2187-2196.
41. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL. The density of muscarinic M1 receptors is decreased in the caudate- putamen of subjects with schizophrenia. Mol Psychiatry 1996;1:54-58.
42. Zavitsanou K, Katsifis A, Mattner F, Xu-Feng H. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004;29:619-625.
43. Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003;160:118-127.
44. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002;7:1083-1091.
45. Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 2007;61:1161-1170.
46. Gibbons AS, Scarr E, McLean CA, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2009;116:184-191.
47. Crook JM, Dean B, Pavey G, Copolov D. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 1999;64:1761-1771.
48. Zavitsanou K, Katsifis A, Yu Y, Huang XF. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 2005;65:397-403.
49. Salah-Uddin H, Scarr E, Pavey G, et al. Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype. Neuropsychopharmacology 2009;34:2156-2166.
50. Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2006;12:232-246.
51. Bymaster FP, Whitesitt CA, Shannon HE, et al. Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 1997;40:158-170.
52. Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008;165:1033-1039.
53. Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M(4) receptor knockout mice and attenuated in muscarinic M(1) receptor knockout mice. Eur J Pharmacol 2009;603:147-149.
54. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacology and Therapeutics 2008;117:232-243.
55. Bymaster FP, Felder CC. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol Psychiatry 2002;7(Suppl 1):S57-S63.
56. Clark AL, Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 1976;58:323-331.
57. Langmead CJ, Austin NE, Branch CL, et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 2008;154:1104-1115.
58. Vanover KE, Veinbergs I, Davis RE. Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. Behav Neurosci 2008;122:570-575.
59. Bradley SR, Lameh J, Ohrmund L, et al. AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 2010;58:365-373.
60. Shirey JK, Brady AE, Jones PJ, et al. A Selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 2009;29:14271-14286.
61. Jones CK, Brady AE, Davis AA, et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 2008;28:10422-10433.
62. Leach K, Loiacono RE, Felder CC, et al. Molecular mechanisms of action and in vivo validation of an m(4) muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 2010;35:855-869.
63. Chan WY, McKinzie DL, Bose S, et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 2008;105:10978-10983.
64. Brady AE, Jones CK, Bridges TM, et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 2008;327:941-953.
65. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34:13-25.
66. Rowntree DW, Nevin S, Wilson A. The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry 1950;13:47-62.
67. Gershon S, Shaw FH. Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet 1961;1:1371-1374.
68. Janowsky DS, El Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972;2:632-635.
69. Dilsaver SC. Cholinergic mechanisms in depression. Brain Res 1986;396:285-316.
70. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006;63:1121-1129.
71. Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: A randomized, placebo-controlled clinical trial. Biol Psychiatry 2010;67:432-438.
72. Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 2010;35:2479-2488.
73. Cannon DM, Carson RE, Nugent AC, et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006;63:741-747.
74. Cannon DM, Klaver JK, Gandhi SK, et al. Genetic variation in cholinergic muscarinic-2 receptor gene modulates M(2) receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry 2010;doi:.
75. Comings DE, Wu S, Rostamkhani M, McGue M, Iacono WG, MacMurray JP. Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Genet 2002;114:527-529.
76. Wang JC, Hinrichs AL, Stock H, et al. Evidence of common and specific genetic effects: Association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Human Mole Genet 2004;13:1903-1911.
77. Luo X, Kranzler HR, Zuo L, Wang S, Blumberg HP, Gelernter J. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: Results from an extended case-control structured association study. Human Mole Genet 2005;14:2421-2434.
78. Cohen-Woods S, Gaysina D, Craddock N, et al. Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder. Human Mole Genet 2009;18:1504-1509.
79. Steinfeld T, Mammen M, Smith JAM, Wilson RD, Jasper JR. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 2007;72:291-302.
80. Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1978;13:23-49.
81. Janowsky DS, El Yousef MK, Davis JM, Hubbard B, Sekerke HJ. Cholinergic reversal of manic symptoms. Lancet 1972;1:1236-1237.
82. Nurnberger J Jr., Berrettini W, Mendelson W, Sack D, Gershon ES. Measuring cholinergic sensitivity: I. Arecoline effects in bipolar patients. Biol Psychiatry 1989;25:610-617.
83. World Health Organization. Management of substance abuse. Available from: [Accessed March 2010].
84. Smith JP. The social impact of drug abuse. 2, 1-49. 1995. United Nations International Drug Control Programme. Position paper for the World Summit for Social Development (Copenhagen, 6-12 March, 1995).
85. Spanagel R, Weiss F. The dopamine hypothesis of reward: Past and current status. Trends Neurosci 1999;22:521-527.
86. Sofuoglu M, Mooney M. Cholinergic functioning in stimulant addiction: Implications for medications development. CNS Drugs 2009;23:939-952.
87. See RE, McLaughlin J, Fuchs RA. Muscarinic receptor antagonism in the basolateral amygdala blocks acquisition of cocaine-stimulus association in a model of relapse to cocaine-seeking behavior in rats. Neurosci 2003;117:477-483.
88. Anney R, Lotfi-Miri M, Olsson C, Reid S, Hemphill S, Patton G. Variation in the gene coding for the M5 muscarinic receptor (CHRM5) influences cigarette dose but is not associated with dependence to drugs of addiction: Evidence from a prospective population based cohort study of young adults. BMC Genetics 2007;8:46.
89. Dick DM, Agrawal A, Wang JC, et al. Alcohol dependence with comorbid drug dependence: Genetic and phenotypic associations suggest a more severe form of the disorder with stronger genetic contribution to risk. Addiction 2007;102:1131-1139.
90. Mobascher A, Rujescu D, Mittelstrass K, et al. Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2) with nicotine addiction. Am J Med Genet B Neuropsychiatr Genet 2010;153B:684-690.
91. de la Garza R, Johanson CE. Effects of haloperidol and physostigmine on self-administration of local anesthetics. Pharmacol Biochem Behav 1982;17:1295-1299.
92. Andersen MB, Werge T, Fink-Jensen A. The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. J Pharmacol Exp Ther 2007;321:1179-1182.
93. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005;100(Suppl 1):68-77.
94. de la Garza R, Mahoney JJ III., Culbertson C, Shoptaw S, Newton TF. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol Biochem Behav 2008;89:200-208.
95. Yeomans J, Forster G, Blaha C. M5 muscarinic receptors are needed for slow activation of dopamine neurons and for rewarding brain stimulation. Life Sci 2001;68:2449-2456.
96. Williams MJ, Adinoff B. The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 2008;33:1779-1797.
97. Bridges TM, Marlo JE, Niswender CM, et al. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J Med Chem 2009;52:3445-3448.
98. Stahl E, Ellis J. Novel allosteric effects of amiodarone at the muscarinic M5 receptor. J Pharmacol Exp Ther 2010; doi:.
99. Citron M. Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 2010;9:387-398.
100. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985;82:4245-4249.
101. Nitsch RM. From acetylcholine to amyloid: Neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration 1996;5:477-482.
102. Liu HC, Hong CJ, Liu TY, Chi CW, Tsai SJ. Association analysis for the muscarinic M1 receptor genetic polymorphisms and Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19:42-45.
103. Quirion R. Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release. J Psychiatry Neurosci 1993;18:226-234.
104. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988;50:1914-1923.
105. Pascual J, Fontan A, Zarranz JJ, Berciano J, Florez JS, Pazos A. High-affinity choline uptake carrier in Alzheimer's disease: Implications for the cholinergic hypothesis of dementia. Brain Res 1991;552:170-174.
106. Warren NM, Piggott MA, Lees AJ, Burn DJ. The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2007;78:571-575.
107. Vogt BA, Crino PB, Vogt LJ. Reorganization of cingulate cortex in Alzheimer's disease: Neuron loss, neuritic plaques, and muscarinic receptor binding. Cerebral Cortex 1992;2:526-535.
108. Piggott MA, Owens J, O'Brien J, et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat 2003;25:161-173.
109. Shiozaki K, Iseki E, Uchiyama H, et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: Relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999;67:209-213.
110. Tsang S, Francis P, Esiri M, Wong P, Chen C, Lai M. Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis. Psychopharmacology 2008;198:251-259.
111. Shiozaki K, Iseki E, Hino H, Kosaka K. Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study. J Neurol Sci 2001;193:23-28.
112. Overk CR, Felder CC, Tu Y, et al. Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. J Chem Neuroanat 2010;40:63-70.
113. Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006;49:671-682.
114. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
115. Ding J, Guzman JN, Tkatch T, et al. RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci 2006;9:832-842.
116. Ruberg M, Ploska A, Javoy-Agid F, Agid Y. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res 1982;232:129-139.
117. Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 1993;60:197-203.
118. Tiraboschi PM, Hansen LAM, Alford MB, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411.
119. Colloby SJ, Pakrasi S, Firbank MJ, et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R, R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. NeuroImage 2006;33:423-429.
120. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: A positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998;65:155-163.
121. Rodri'guez-Puertas R, Pazos A, Pascual J. Cholinergic markers in degenerative parkinsonism: Autoradiographic demonstration of high-affinity choline uptake carrier hyperactivity. Brain Res 1994;636:327-332.
122. Warren NM, Piggott MA, Lees AJ, Burn DJ. Muscarinic receptors in the thalamus in progressive supranuclear palsy and other neurodegenerative disorders. J Neuropathol Exp Neurol 2007;66:399-404.
123. Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: A cohort study. J Neurol Neurosurg Psychiatry 2010;81:160-165.
124. Ott BR, Lannon MC. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 1992;15:322-325.
125. Betz A, McLaughlin P, Burgos M, Weber S, Salamone J. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: Possible role of M4 receptors. Psychopharmacology 2007;194:347-359.
126. Varoli L, Andreani A, Burnelli S, et al. Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett 2008;18:2972-2976.